What is CRNX (CRNX) stock price today?

CRNX (CRNX) is currently trading at $84.95, up 0% today.

What is CRNX P/E ratio?

CRNX's P/E ratio is -16.80. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CRNX return on equity (ROE)?

CRNX's return on equity (ROE) is -44.22%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CRNX's market cap?

CRNX has a market capitalization of $9.00B.

NASDAQ · Biotechnology

CRNX (CRNX) Stock

$84.95 +0.00% NASDAQ: CRNX Healthcare

Valuation

Metric	Value
Price	$84.95
Market Cap	$9.00B
P/E Ratio	-16.80
P/B Ratio	7.51
P/S Ratio	213.26
EPS (TTM)	$0.00
52-Week High	$84.99
52-Week Low	$31.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-44.22%
ROA	-37.95%
ROCE	-44.21%
Gross Margin	-6450.00%
Operating Margin	-13.08%
Net Margin	-27.47%
Debt/Equity	0.04
Current Ratio	18.60

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$1.0M	$5.0M	$4.0M	$1.0M	$8.0M
Operating Profit	$-108.0M	$-168.0M	$-223.0M	$-339.0M	$-517.0M
Net Profit	$-108.0M	$-164.0M	$-215.0M	$-298.0M	$-465.0M
EPS	$-2.80	$-3.15	$-3.69	$-3.69	$-4.95
Op Margin	-9990.9%	-3544.1%	-5547.2%	-32613.5%	-6714.8%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$351.0M	$352.0M	$635.0M	$1.4B	$1.1B
Total Liabilities	$19.0M	$36.0M	$96.0M	$110.0M	$143.0M
Cash	$201.0M	$33.0M	$55.0M	$265.0M	$102.0M
Borrowings	$4.0M	$3.0M	$52.0M	$52.0M	$49.0M

Latest News

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy? Motley Fool · Jul 13, 2026 Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse MarketBeat · Jul 11, 2026 Why This Pharmaceutical Stock Jumped Close to 100% This Week Motley Fool · Jul 10, 2026 Why Crinetics Stock Soared 99% This Week 24/7 Wall St. · Jul 9, 2026 Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says MT Newswires · Jul 8, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-89.0M	$-115.0M	$-166.0M	$-226.0M	$-378.0M
Investing Cash Flow	$-57.0M	$-176.0M	$-205.0M	$-579.0M	$168.0M
Financing Cash Flow	$3.0M	$5.0M	$20.0M	$40.0M	$0
Net Cash Flow	$108.0M	$-167.0M	$22.0M	$210.0M	$-164.0M
Free Cash Flow	$-89.0M	$-117.0M	$-171.0M	$-230.0M	$-384.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.83
EV / EBITDA	-17.65
FCF Yield	-4.73%
Quick Ratio	15.53
Interest Coverage	0.00
Return 1Y	176.80%
Return 3Y	413.56%
Return 5Y	262.25%

Ownership

Insiders Held1.59%

Institutions Held119.81%

Institutions Float Held121.75%

Institutional Holder	Shares	Report Date
FMR, LLC	15,759,799	2026-03-31
Blackrock Inc.	8,478,815	2026-03-31
Farallon Capital Management LLC	8,338,098	2026-03-31
Wellington Management Group, LLP	8,157,204	2026-03-31
Driehaus Capital Management, LLC	6,395,922	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACAD	$28.89	-0.07%	8.94	$4.95B	0.00%
AKROAkero Therapeutics, Inc.	$54.65	+0.00%	-19.87	$4.50B	0.00%
DYN	$25.10	-1.30%	-7.64	$4.69B	0.00%
IMVT	$39.90	-2.25%	-14.48	$8.24B	0.00%
KYMR	$119.05	+0.20%	-36.35	$9.79B	0.00%

About CRNX

CRNX is led by CEO R. Scott Struthers, employs 594 people, headquartered in San Diego, US, publicly traded since 2018.

CRNX stock trades at $84.95 with a market capitalization of $9.00B. The stock is valued at a price-to-earnings (P/E) ratio of -16.80, price-to-book of 7.51, price-to-sales of 213.26. Over the past 52 weeks the stock has ranged between $31.00 and $84.99, and currently trades at its 52-week high.

On profitability, CRNX generates a return on equity (ROE) of -44.22%, return on capital employed of -44.21%, an operating margin of -13.08%, a net profit margin of -27.47%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides